CMAJ • July 18, 2006; 175 (2). doi:10.1503/cmaj.060244.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gillespie, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gillespie, K. M.
Related Collections
Right arrow Diabetes
Right arrow Genetics

Type 1 diabetes: pathogenesis and prevention

Kathleen M. Gillespie

Kathleen Gillespie is a lecturer with the Department of Clinical Science at North Bristol, University of Bristol, UK.


Figure 118
View larger version (17K):

[in a new window]
  		Fig. 1: Geographic variation in annual incidence of type 1 diabetes.

 

Figure 218
View larger version (80K):

[in a new window]
  		Fig. 2: Representation of the process whereby antigen (in this case peptides of proinsulin) is presented to CD4 T cells by human leukocyte antigen (HLA) class II molecules on the antigen presenting cell. This results in T-cell activation. In this diagram the 4 major genes associated with type 1 diabetes are present. CTLA-4 is an inhibitor of T-cell activation, as is lymphoid tyrosine phosphatase (LYP), which is encoded by the gene PTPN22. The complex of LYP–C-terminal Src kinase (CSK) inhibits Lck signalling after engagement of the T-cell antigen receptor (TCR). Photo by: Lianne Friesen and Nicholas Woolridge

 

Figure 318
View larger version (25K):

[in a new window]
  		Fig. 3: Potential targets for therapeutic intervention of type 1 diabetes.